Alzheimer's disease, but not limited to, corticobasal degeneration and mild cognitive impairment., frontotemporal dementia, Neurodegenerative disorders with Tau-pathology; including, progressive supranuclear palsy
Conditions
Brief summary
Detection of specific signal of 18F-RO6958948 or 18F-Flutemetamol in patients with neurodegenerative disease or healthy volunteers.
Detailed description
- 18F-RO6958948 or 18F-Flutemetamol PET brain:cerebellar uptake ratios measured with a priori VOI analysis in subjects with neurodegenerative disease compared to healthy volunteers, - Associations of 18F-RO6958948 or 18F-Flutemetamol brain uptake ratios measured by VOI analysis with other diagnostic methods, including CSF biomarkers, cognitive tests and MRI findings, - Regional differences in distribution of 18F-RO6958948 or 18FFlutemetamol brain uptake between different neurodegenerative disease conditions
Interventions
Sponsors
Region Skane
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of specific signal of 18F-RO6958948 or 18F-Flutemetamol in patients with neurodegenerative disease or healthy volunteers. | — |
Secondary
| Measure | Time frame |
|---|---|
| - 18F-RO6958948 or 18F-Flutemetamol PET brain:cerebellar uptake ratios measured with a priori VOI analysis in subjects with neurodegenerative disease compared to healthy volunteers, - Associations of 18F-RO6958948 or 18F-Flutemetamol brain uptake ratios measured by VOI analysis with other diagnostic methods, including CSF biomarkers, cognitive tests and MRI findings, - Regional differences in distribution of 18F-RO6958948 or 18FFlutemetamol brain uptake between different neurodegenerative disease conditions | — |
Countries
Sweden
Outcome results
None listed